
Opinion|Videos|January 28, 2025
Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery
Author(s)Jeffrey V. Matous, MD
Jeffrey V. Matous, MD, discusses how best practices in transitioning care between academic and community centers can enhance patient outcomes when receiving bispecific antibodies, and the critical role managed care organizations play in facilitating cost-effective integration of these therapies into community settings through optimized partnerships.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What best practices can improve transitions of care between academic and community centers for patients receiving bispecific antibodies?
- What role do managed care organizations play in facilitating the integration of bispecific antibody therapies into community settings, and how can partnerships be optimized to ensure cost-effective care delivery?
Advertisement
Related to this article

Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.

Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.

Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.

CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Advertisement
Advertisement
Trending on AJMC
1
Lung Cancer Progress Drives Down US Cancer Death Rates
2
Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care
3
All 50 States Apply for CMS's GENEROUS Model, With $64.3B in Savings Projected
4
Semaglutide Adherence Falls Once Out-of-Pocket Costs Top $75 a Month
5



